Bon Secours Liver Institute of Richmond

Richmond, Virginia 23226

1 studies enrolling now · 13 studies all time

What they study most

Alcoholic Hepatitis, Bile Duct Stricture, Biliary Tract Diseases, Cholangitis, Cholestasis, Cirrhosis, Cirrhosis, Liver, Hepatic Cirrhosis, Hepatitis, Hepatitis B, Hepatocellular Cancer, Hepatocellular Carcinoma

Studies at this site

• Study to Evaluate the Safety and Efficacy of Larsucosterol in Participants With Alcohol-associated Hepatitis (AH) — Recruiting now
• A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES) — Running, not enrolling
• A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE) — Running, not enrolling
• ALTUS: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk — Running, not enrolling
• An Observational Study of Patients With Chronic Hepatitis B (CHB) Infection — Stopped early
• A Study to Evaluate the Safety, and Tolerability, and Efficacy of Seladelpar in Patients With PSC — Stopped early
• A Phase 2b Study in Subjects With Alcoholic Hepatitis to Evaluate Safety and Efficacy of DUR-928 Treatment — Completed
• Open-Label Study of HTD1801 in Adult Subjects With Primary Biliary Cholangitis — Completed
• A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease Patients — Completed
• Study to Evaluate the Efficacy and Safety of CC-90001 in Participants With Non-alcoholic Steatohepatitis (NASH) and Liver Fibrosis — Stopped early
• A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Liver Cirrhosis — Completed
• A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver Fibrosis — Completed
• Study to Assess Safety & Efficacy of GKT137831 in Patients With Primary Biliary Cholangitis Receiving Ursodiol. — Completed